ClinicalTrials.gg
RecruitingNCT07637682Updated Jun 18, 2026

Percutaneous Neurostimulation in Knee Osteoarthritis

An interventional study of nerve stimulation using a nerve stimulator to the genicular nerve and nerve stimulation using a nerve stimulator to the saphenous nerve in Osteoarthritis (OA) of the Knee and Neuromodulation, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Tanta University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Osteoarthritis with a site in Egypt — 12 open to participants now, 12 under way, 1 of them phase 3. Osteoarthritis · Egypt.

Planned enrollment
5th of 27
100 · median 60
Started
2026
with 6 others
No phase
23 of 33
10 open now
Primary completion
2026-11
later than 7 of 11 live
Registered
31st of 33
by date

Among the 33 studies in Osteoarthritis with a site in Egypt, this one is the 5th largest by planned enrollment of the 27 interventional ones that give a count, is one of 7 that started in 2026, is one of 23 with no phase, reaches primary completion later than 7 of the 11 other live ones, and was the 31st registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

12 of the 33 studies in Osteoarthritis with a site in Egypt are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Osteoarthritis with a site in Egypt, or all of them as a file.
02

Study summary

Peripheral nerve stimulation (PNS) is a drug-free pain management procedure that uses electrical impulses to target specific nerves and block pain signals. PNS helps decrease perception of pain, providing real answers to patients dealing with chronic knee pain. The case study discussed in this presentation is of the use of PNS targeting the superior lateral genicular nerve and the saphenous nerve for a patient with moderate to severe knee pain from osteoarthritis

03

Conditions studied

  • Osteoarthritis (OA) of the Knee
  • Neuromodulation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. adults between the ages of 30 and 70 years with a clinical diagnosis of moderate to severe knee OA who suffered knee pain.
  2. Patients who cannot afford intra-articular injections or radiofrequency ablation (RFA).
  3. patients who had failed 2 different oral pain medications and 6 weeks of physical therapy.

Exclusion criteria

Exclusion Criteria:

  1. Patients with OA show improvement in pain after physiotherapy.
  2. patients evaluated by an orthopaedic surgeon and deemed to be surgical candidates due to knee pathologies other than OA.
  3. pregnant patients.
  4. patients on anticoagulation therapy, who were not permitted to stop anticoagulation.
  5. patients with previous trauma, neurological or endocrine diseases like diabetes mellitus, and knee tumors; and patients with inflammatory arthritis.
  6. people who had received an intra-articular knee injection within the last 6 months.
  7. Patients with tendon tears, bursitis, or calcified tendonitis as proven by imaging.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    transcutaneous nerve stimulation using a nerve stimulator to the genicular nerve block

    Device: nerve stimulation using a nerve stimulator to the genicular nerve

  • Experimental
    transcutaneous nerve stimulation using a nerve stimulator to the saphenous nerve

    Device: nerve stimulation using a nerve stimulator to the saphenous nerve

Interventions

  • Devicenerve stimulation using a nerve stimulator to the genicular nerve

    temporary transcutaneous nerve stimulation using a nerve stimulator to the genicular nerve, with settings 2Hz, 0.2mA, 1ms, where the nerve is stimulated for 4 to 6 minutes.

  • Devicenerve stimulation using a nerve stimulator to the saphenous nerve

    temporary transcutaneous nerve stimulation using a nerve stimulator to the saphenous nerve, with settings 2Hz, 0.2mA, 1ms, where the nerve is stimulated for 4 to 6 minutes.

06

What researchers measure

Primary outcomes

  1. Change in visual analogue scale after intervention.

    Decrement (clinical improvement) in visual analogue scale (VAS) immediately after intervention. The participant's knee discomfort was measured using a VAS. Participants were asked to score their level of pain on a 100-mm horizontal line, ranging from 0 to 100.

    Time frame: immediately after intervention.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Plan to Share IPD: "Yes" Plan Description: "Data obtained through this study may be provided to qualified researchers with academic interest in scapular dyskinesis. Data or samples shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e., a material transfer agreement) are prerequisites to the sharing of data with the requesting party. Results will be published by the investigators in academic journal.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis

Access criteria: Access to trial IPD can be requested by qualified researchers engaging in independent scientific research and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Nov 2026, 5 months after the start.

Of 578 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 5 months is below that.

Counting every sponsor, half of 713 studies reached it within 28 months; a quarter within 11 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2026
First posted
Jun 10, 2026
StartActual
Jun 2, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07637682
Lead sponsor
Tanta University
Responsible party
Aliaa Mamdouh Abdelaziz Farag (Lecturer, Tanta University) — Principal investigator
First posted
Jun 10, 2026
Start date
Jun 2, 2026
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Jun 18, 2026

Study contacts

Aliaa Mamdouh Abdelaziz Farag, MD
Contact
aliaa.mamdouh@med.tanta.edu.eg
+201069468486

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion